CytomX Therapeutics, Inc.
CTMX
$0.9605
-$0.0059-0.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 13.94% | 33.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.94% | 33.12% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 13.94% | 33.12% | |||
| SG&A Expenses | -29.28% | -5.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -30.38% | -12.65% | |||
| Operating Income | 330.04% | 148.64% | |||
| Income Before Tax | 226.69% | 189.42% | |||
| Income Tax Expenses | 1.64% | 19.61% | |||
| Earnings from Continuing Operations | 229.08% | 187.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 229.08% | 187.79% | |||
| EBIT | 330.04% | 148.64% | |||
| EBITDA | 298.50% | 156.80% | |||
| EPS Basic | 226.56% | 187.53% | |||
| Normalized Basic EPS | 223.94% | 189.31% | |||
| EPS Diluted | 226.56% | 184.25% | |||
| Normalized Diluted EPS | 224.71% | 189.10% | |||
| Average Basic Shares Outstanding | 0.76% | 0.25% | |||
| Average Diluted Shares Outstanding | 0.63% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||